Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerwin

Showing results (911-920 of 984) with videos related to

Pageof 99
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 8, 2022
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysisFrederik O Meeuwes, Mirian Brink, Marjolein W M van der Poel, et al.
Cancer Cell|September 25, 2018
Prospective Isolation and Characterization of Genetically and Functionally Distinct AML SubclonesBauke de Boer, Janine Prick, Maurien G Pruis, et al.
Alzheimer'S Research & Therapy|October 3, 2025
Usability and feasibility of ADappt: a digital toolkit to support communication on diagnosis and prognosis in memory clinicsHeleen M A Hendriksen, Tanja J de Rijke, Aniek M van Gils, et al.
Transplantation and Cellular Therapy|December 1, 2025
Decitabine Conditioning Improves Natural Killer Cell Maturation and Limits CD8<sup>+</sup> T Cell Terminal Differentiation Post-Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia PatientsJesper van Eck van der Sluijs, Diede van Ens, Ayla Grotens, et al.
The Journal of Pathology|May 27, 2015
Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesotheliomaViktoria Laszlo, Mir Alireza Hoda, Tamas Garay, et al.
Blood|April 15, 2025
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapyNaval G Daver, Paresh Vyas, Gerwin A Huls, et al.
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
Nature Materials|January 27, 2004
Flexible active-matrix displays and shift registers based on solution-processed organic transistorsGerwin H Gelinck, H Edzer A Huitema, Erik van Veenendaal, et al.
Seminars in Arthritis and Rheumatism|October 2, 2022
International, multidisciplinary Delphi consensus recommendations on non-pharmacological interventions for fibromyalgiaBurak Kundakci, Michelle Hall, Fabiola Atzeni, et al.
Blood Neoplasia|April 20, 2026
Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemiaNiels Westra, Elena Ropero Cerro, Edwin Schilder, et al.
Pageof 99

Showing results (911-920 of 984) with videos related to

Sort By:
Pageof 99
European Journal of Cancer (Oxford, England : 1990)|October 8, 2022
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysisFrederik O Meeuwes, Mirian Brink, Marjolein W M van der Poel, et al.
Cancer Cell|September 25, 2018
Prospective Isolation and Characterization of Genetically and Functionally Distinct AML SubclonesBauke de Boer, Janine Prick, Maurien G Pruis, et al.
Alzheimer'S Research & Therapy|October 3, 2025
Usability and feasibility of ADappt: a digital toolkit to support communication on diagnosis and prognosis in memory clinicsHeleen M A Hendriksen, Tanja J de Rijke, Aniek M van Gils, et al.
Transplantation and Cellular Therapy|December 1, 2025
Decitabine Conditioning Improves Natural Killer Cell Maturation and Limits CD8<sup>+</sup> T Cell Terminal Differentiation Post-Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia PatientsJesper van Eck van der Sluijs, Diede van Ens, Ayla Grotens, et al.
The Journal of Pathology|May 27, 2015
Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesotheliomaViktoria Laszlo, Mir Alireza Hoda, Tamas Garay, et al.
Blood|April 15, 2025
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapyNaval G Daver, Paresh Vyas, Gerwin A Huls, et al.
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
Nature Materials|January 27, 2004
Flexible active-matrix displays and shift registers based on solution-processed organic transistorsGerwin H Gelinck, H Edzer A Huitema, Erik van Veenendaal, et al.
Seminars in Arthritis and Rheumatism|October 2, 2022
International, multidisciplinary Delphi consensus recommendations on non-pharmacological interventions for fibromyalgiaBurak Kundakci, Michelle Hall, Fabiola Atzeni, et al.
Blood Neoplasia|April 20, 2026
Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemiaNiels Westra, Elena Ropero Cerro, Edwin Schilder, et al.
Pageof 99